SB 258719

• Description :

  SB 258719 is a selective 5-HT7 receptor antagonist with high affinity (pKi=7.5) for the receptor. SB 258719 can be used for the research of cancer and neurological disease[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  5-HT Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cancer; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/SB_258719.html

• Purity :

  99.0

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  O=S(C1=CC=CC(C)=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O

• Molecular Formula :

  C18H30N2O2S

• Molecular Weight :

  338.51

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Thomas DR, et al. Functional characterisation of the human cloned 5-HT7 receptor (long form) ; antagonist profile of SB-258719. Br J Pharmacol. 1998;124 (6) :1300-1306.|[2]Guscott MR, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44 (8) :1031-1037.|[3]Fatima S, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol Oncol. 2016;10 (2) :195-212.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  5-HT7 Receptor; MUC3

• CAS Number :

  [195199-95-2]